{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:24:08Z","timestamp":1774679048988,"version":"3.50.1"},"reference-count":39,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2026,3,31]]},"DOI":"10.7883\/yoken.jjid.2025.086","type":"journal-article","created":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T18:07:26Z","timestamp":1751220446000},"page":"49-55","source":"Crossref","is-referenced-by-count":0,"title":["SARS-CoV-2 Spike-specific T Cell Responses Following COVID-19 Vaccination in Japanese People Living with HIV"],"prefix":"10.7883","volume":"79","author":[{"given":"Mark","family":"Ndubi","sequence":"first","affiliation":[{"name":"Joint Research Center for Human Retrovirus Infection, Division of Infection and Immunity, Kumamoto University, Japan"},{"name":"Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mako","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Joint Research Center for Human Retrovirus Infection, Division of Infection and Immunity, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Ngare","sequence":"additional","affiliation":[{"name":"Joint Research Center for Human Retrovirus Infection, Division of Infection and Immunity, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Motozono","sequence":"additional","affiliation":[{"name":"Joint Research Center for Human Retrovirus Infection, Division of Infection and Immunity, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumi","family":"Minami","sequence":"additional","affiliation":[{"name":"Internal Medicine, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamasa","family":"Ueno","sequence":"additional","affiliation":[{"name":"Joint Research Center for Human Retrovirus Infection, Division of Infection and Immunity, Kumamoto University, Japan"},{"name":"Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4631","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Alrubayyi A, Gea-Mallorqu\u00ed E, Touizer E, et al. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. Nat Commun. 2021;12:5839.","DOI":"10.1038\/s41467-021-26137-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Spinelli MA, Jones BLH, Gandhi M. COVID-19 outcomes and risk factors among people living with HIV. Curr HIV\/AIDS Rep. 2022;19:425\u2013432.","DOI":"10.1007\/s11904-022-00618-w"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Al Meslamani AZ. Antiretroviral therapy response: exploring the potential influence of SARS-CoV-2. Expert Rev Clin Pharmacol. 2024;17:533\u2013536.","DOI":"10.1080\/17512433.2024.2322984"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Yang X, Su B, Zhang X, et al. Incomplete immune reconstitution in HIV\/AIDS patients on antiretroviral therapy: Challenges of immunological non-responders. J Leukoc Biol. 2020;107:597-612.","DOI":"10.1002\/JLB.4MR1019-189R"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Garrido-Rodr\u00edguez V, Bulnes-Ramos \u00c1, Olivas-Mart\u00ednez I, et al. The persistence of low CD4\/CD8 ratio in chronic HIV-infection, despite ART suppression and normal CD4 levels, is associated with pre-therapy values of inflammation and thymic function. J Microbiol Immunol Infect. 2024;57:854\u2013867.","DOI":"10.1016\/j.jmii.2024.08.007"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mullender C, da Costa KAS, Alrubayyi A, et al. SARS-CoV-2 immunity and vaccine strategies in people with HIV. Oxf Open Immunol. 2022;3:iqac005.","DOI":"10.1093\/oxfimm\/iqac005"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Pallikkuth S, de Armas L, Rinaldi S, et al. T follicular helper cells and B cell dysfunction in aging and HIV-1 infection. Front Immunol. 2017;8:1380.","DOI":"10.3389\/fimmu.2017.01380"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Innis EA, Levinger C, Szaniawski MA, et al. Pharmacologic control of homeostatic and antigen-driven proliferation to target HIV-1 persistence. Biochem Pharmacol. 2021;194:114816.","DOI":"10.1016\/j.bcp.2021.114816"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. McCune JM. The dynamics of CD4+ T-cell depletion in HIV disease. Nature. 2001;410:974\u2013979. doi: https:\/\/doi.org\/10.1038\/35073648","DOI":"10.1038\/35073648"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Li N, Zheng HY, Li W, et al. Limited restoration of T cell subset distribution and immune function in older people living with HIV-1 receiving HAART. Immun Ageing. 2025;22:3.","DOI":"10.1186\/s12979-024-00497-2"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kaufmann DE, Walker BD. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol. 2009; 182:5891\u20135897.","DOI":"10.4049\/jimmunol.0803771"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Cherneha M, Zydek I, Bra\u00df P, et al. Immunogenicity of the monovalent omicron XBB. 1.5-adapted BNT162b2 COVID-19 vaccine in people living with HIV (PLWH). Vaccines. 2024;12:785.","DOI":"10.3390\/vaccines12070785"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sister\u00e9-Or\u00f3 M, Andrade N, Wortmann DDJ, et al. Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination. Front Immunol. 2022;13:994173.","DOI":"10.3389\/fimmu.2022.994173"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ruta S, Popescu CP, Matei L, et al. SARS-CoV-2 Humoral and Cellular Immune Responses in People Living with HIV. Vaccines. 2024;12:663.","DOI":"10.3390\/vaccines12060663"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Benet S, Blanch-Lombarte O, Ainsua-Enrich E, et al. Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PWH with poor immune reconstitution. J Infect Dis. 2022;226:1913\u20131923.","DOI":"10.1093\/infdis\/jiac406"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bowyer G, Rampling T, Powlson J, et al. Activation-induced markers detect vaccine-specific CD4+ T cell responses not measured by assays conventionally used in clinical trials. Vaccines. 2018;6:50.","DOI":"10.3390\/vaccines6030050"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Motozono C, Toyoda M, Tan TS, et al. The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition. Nat Commun. 2022;13:5440.","DOI":"10.1038\/s41467-022-33068-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nguema L, Picard F, El Hajj M, et al. Subunit protein CD40. SARS. CoV2 vaccine induces SARS-CoV-2-specific stem cell-like memory CD8+ T cells. EBioMedicine. 2025;111:105479.","DOI":"10.1016\/j.ebiom.2024.105479"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Binayke A, Zaheer A, Vishwakarma S, et al. A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation. NPJ Vaccines. 2024;9:3.","DOI":"10.1038\/s41541-023-00794-9"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ngare I, Tan TS, Toyoda M, et al. Factors associated with neutralizing antibody responses following 2-dose and 3rd booster monovalent COVID-19 vaccination in Japanese people living with HIV. Viruses. 2024;16:555.","DOI":"10.3390\/v16040555"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Palmer BE, Blyveis N, Fontenot AP, et al. Functional and phenotypic characterization of CD57+CD4+ T cells and their association with HIV-1-induced T cell dysfunction1. J Immunol. 2005;175:8415\u20138423.","DOI":"10.4049\/jimmunol.175.12.8415"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Pallikkuth S, Williams E, Pahwa R, et al. Association of Flu specific and SARS-CoV-2 specific CD4 T cell responses in SARS-CoV-2 infected asymptomatic heath care workers. Vaccine. 2021;39:6019\u20136024.","DOI":"10.1016\/j.vaccine.2021.08.092"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Islam N, Sheils NE, Jarvis MS, et al. Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine. Nat Commun. 2022;13:2377.","DOI":"10.1038\/s41467-022-30059-3"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kaiser RA, Haller MC, Apfalter P, et al. Comparison of BNT162b2 (Pfizer\u2013BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients. Kidney Int. 2021;100:697-698.","DOI":"10.1016\/j.kint.2021.07.004"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Naranbhai V, Garcia-Beltran WF, Chang CC, et al. Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2, and Ad26. COV2. S COVID-19 vaccines. J Infect Dis. 2022;225:1141\u20131150.","DOI":"10.1093\/infdis\/jiab593"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. S\u00f8gaard OS. Deciphering the association between HIV-specific immunity and immune reconstitution. EBioMedicine. 2021;67:103350.","DOI":"10.1016\/j.ebiom.2021.103350"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Schuetz A, Deleage C, Sereti I, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 2014;10:e1004543.","DOI":"10.1371\/journal.ppat.1004543"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. K\u00f6k A, Hocqueloux L, Hocini H, et al. Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients. Mucosal Immunol. 2015;8:127\u2013140.","DOI":"10.1038\/mi.2014.50"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Guerrera G, Picozza M, D\u2019Orso S, et al. BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype. Sci Immunol. 2021;6:eabl5344.","DOI":"10.1126\/sciimmunol.abl5344"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Zuo J, Dowell AC, Pearce H, et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol. 2021;22:620\u2013626.","DOI":"10.1038\/s41590-021-00902-8"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Sette A, Sidney J, Crotty S. T cell responses to SARS-CoV-2. Annu Rev Immunol. 2023;41:343\u2013373.","DOI":"10.1146\/annurev-immunol-101721-061120"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Tarke A, Sidney J, Methot N, et al. Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals. Cell Rep Med. 2021;2:100355.","DOI":"10.1016\/j.xcrm.2021.100355"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Loyal L, Braun J, Henze L, et al. Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science. 2021;374:eabh1823.","DOI":"10.1126\/science.abh1823"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Jiang W, Jiang Y, Sun H, et al. Structural insight into broadening SARS-CoV-2 neutralization by an antibody cocktail harboring both NTD and RBD potent antibodies. Emerg Microbes Infect. 2024;13:2406300.","DOI":"10.1080\/22221751.2024.2406300"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Dickey TH, Tang WK, Butler B, et al. Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response. Sci Adv. 2022;8:eabq8276.","DOI":"10.1126\/sciadv.abq8276"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sharma D, Rawat P, Greiff V, et al. Predicting the immune escape of SARS-CoV-2 neutralizing antibodies upon mutation. Biochim Biophys Acta Mol Basis Dis. 2024;1870:166959.","DOI":"10.1016\/j.bbadis.2023.166959"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Dub\u00e9 M, Tastet O, Dufour C, et al. Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4+ and CD8+ T cells. Cell Host Microbe. 2023;31:1507\u20131522.","DOI":"10.1016\/j.chom.2023.08.006"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Bie\u0144kowski C, \u017bak Z, Fijo\u0142ek F, et al. Immunological and Clinical Responses to Vaccinations among adults living with HIV. Life. 2024;14:540.","DOI":"10.3390\/life14050540"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Brumme ZL, Mwimanzi F, Lapointe HR, et al. Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. NPJ Vaccines. 2022;7:28.","DOI":"10.1038\/s41541-022-00452-6"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/79\/2\/79_JJID.2025.086\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T03:59:43Z","timestamp":1774670383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/79\/2\/79_JJID.2025.086\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2025.086","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"JJID.2025.086"}}